The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how
much of the drug gets into the blood and how long it takes the body to get rid of it) of
single doses of EGT0001474 given to patients with Type 2 diabetes. The study will also
evaluate how EGT0001474 affects the amount of glucose produced by the body in the urine.